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ABSTRACT
Anti-miRs are oligonucleotide inhibitors comple-
mentary to miRNAs that have been used extensively
as tools to gain understanding of specific miRNA
functions and as potential therapeutics. We
showed previously that peptide nucleic acid (PNA)
anti-miRs containing a few attached Lys residues
were potent miRNA inhibitors. Using miR-122 as
an example, we report here the PNA sequence and
attached amino acid requirements for efficient
miRNA targeting and show that anti-miR activity is
enhanced substantially by the presence of a
terminal-free thiol group, such as a Cys residue, pri-
marily due to better cellular uptake. We show that
anti-miR activity of a Cys-containing PNA is ac-
hieved by cell uptake through both clathrin-
dependent and independent routes. With the aid of
two PNA analogues having intrinsic fluorescence,
thiazole orange (TO)-PNA and [bis-o-(aminoethoxy)-
phenyl]pyrrolocytosine (BoPhpC)-PNA, we explored
the subcellular localization of PNA anti-miRs and
our data suggest that anti-miR targeting of miR-
122 may take place in or associated with endosomal
compartments. Our findings are valuable for further
design of PNAs and other oligonucleotides as
potent anti-miR agents.
INTRODUCTION
MicroRNAs (miRNAs) are endogenous small non-coding
RNAs that regulate gene expression post-transcriptionally.
Many miRNAs have been described in different species
and with functions associated with a wide range of cellu-
lar processes and human diseases (1,2). Although alter-
native miRNA biogenesis pathways have been uncovered
recently (3–5), the principal biosynthetic route involves
processing in the nucleus of an initial primary miRNA
transcript (pri-miRNA) by an RNase III type enzyme,
Drosha, resulting in a  70–80nt long stem-loop
precursor-miRNA (pre-miRNA). The pre-miRNA is
then exported to the cytosol where another RNase III
type enzyme, Dicer, removes the loop to give an imper-
fectly paired double-stranded mature miRNA of  22 nt
long. One miRNA strand is then selected by a
ribonucleoprotein complex necessary for miRNA activity,
miRISC (6). Upon loading in miRISC, miRNAs bind to
the 30-untranslated region (UTR) of their mRNA targets
and repress their expression by inducing mRNA degrad-
ation and/or by preventing mRNA translation (7–9).
MiRNA targets are recognized by the miRNA mainly
through the miRNA ‘seed’ sequence comprising nucleo-
tides 2–8 at the 50-end of the miRNA (10). miRNA
loading into miRISC pre-organizes the seed sequence for
target recognition (11,12). Apart from these nucleotides,
there is no need for extensive complementarity between
the miRNA and its mRNA target, which thus allows one
miRNA to be able to regulate many mRNAs (10).
Although the cellular site of mRNA repression by
miRNAs is unclear, it is believed that miRNAs become
associated with certain cytoplasmic foci and endosomal
compartments. Cytosolic foci known as P-bodies contain
not only miRNAs and their target mRNAs but also other
key components of miRISC such as Argonaute proteins
(Ago) and Trinucleotide-Repeat-Containing-Gene-6
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GW182, a protein that binds Ago), which were found
to be independent of P-bodies, also contain the same
miRISC components, often associated with multivesicular
body (MVB)-like membranes (14). MiRNAs have also
been found in exosomes (14,15) and more recently also
in the nucleus (16) and mitochondria (17).
Oligonucleotide analogues (ON) complementary to
miRNAs can inhibit their function and are known as
anti-miRs. Anti-miRs have been used extensively as
tools to gain understanding of speciﬁc miRNA functions
and as potential therapeutics (18–23). The ﬁrst anti-miR
chemistries were based on 20-O-methyl ribonucleosides
(18,24–27). Later, other anti-miR chemistries became more
promising, such as 20-O-methoxyethyl (MOE) (19,28)
and 20-ﬂuoro/20-methoxyethyl mixmers (20F/MOE) (29),
charge neutral ONs, such as Peptide Nucleic Acids
(PNA) (22,30–32) and high-afﬁnity Locked Nucleic Acid
(LNA) in mixmers with DNA (21,23,33,34), OMe
(30,32,34) or MOE (28,29). To date only an LNA/DNA
mixmer has advanced to clinical trials (Santaris Pharma
News release 23 September 2010).
Further development of anti-miRs as reagents and
therapeutics is likely to beneﬁt from an improved under-
standing of the anti-miR biology: the chemical structure
requirements for anti-miR targeting as well as mechanistic
aspects, such as cell uptake and subcellular localization.
To this end, we have chosen to study miR-122, which is a
23-mer-long, liver-speciﬁc miRNA that has generated con-
siderable interest as a therapeutic target (23). Inhibition of
miR-122 has been shown to lead to lowering of plasma
cholesterol levels in mice and primates (18,19,21).
Furthermore, miR-122 is required for hepatitis C virus
(HCV) replication (26), such that treatment with an
LNA/DNA anti-miR leads to suppression of HCV
viremia in primates (23).
We and others have shown that PNAs are highly effect-
ive as anti-miRs (22,30–32). We reported that a 23-mer
PNA fully complementary to miR-122, containing three
Lys residues at the C-terminus and one Lys at the
N-terminus as well as a Cys residue for post-synthetic
modiﬁcations (Cys-K-PNA23mer-K3) effectively in-
hibited miR-122 in a human hepatic cell line (Huh7) and
in primary rat hepatocytes without the use of any trans-
fection agents, as seen by up-regulation of miR-122
mRNA targets (30). More recently, we showed that the
same PNA anti-miR compared as well in inhibitory
activity in a miR-122-sensitive luciferase reporter system
in Huh7 cells as an LNA/OMe anti-miR containing
phosphorothioate (PS) linkages, each delivered in the
absence of transfection agents (32). We also showed efﬁ-
cient inhibition of miR-155 by a 23-mer PNA anti-miR
having the structure K-PNA23mer-K3 in B-cells and in
mice, again without use of transfection agents (22).
In our new studies, we have explored various aspects of
targeting of miR-122 by cationic PNA anti-miRs. We ﬁrst
addressed the PNA sequence and attached amino acid re-
quirements for efﬁcient miRNA targeting and show that
activity of the PNA anti-miR is enhanced substantially by
the presence of a free thiol group. We demonstrate that
this is due primarily to better cellular uptake, an unantici-
pated discovery. We also investigated the mechanisms of
cellular uptake for Cys-K-PNA-K3 and shed light on a
possible subcellular compartment where the targeting of
miR-122 by PNA anti-miRs might occur. Our data should
prove useful for further design of PNAs and other ONs as
potent anti-miR agents.
MATERIALS AND METHODS
PNA synthesis
PNA ONs were synthesised as previously described (22)
and their sequences are shown in Table 1, with the excep-
tions of Met-K-PNA23mer-K3, Ser-K-PNA23mer-K3
and MPA-K-PNA23mer-K3. These three PNA ONs had
the same sequence as Cys-K-PNA23mer-K3 but the
terminal Cys residue was replaced by methionine, serine
or 3-mercaptopropionic acid, respectively. RNA oligo-
nucleotide having the same sequence as miR-122 (50-UG
GAGUGUGACAAUGGUGUUUGU-30) was purchased
Table 1. Sequences of PNAs used in this study. Indicated in the grey box is the miR-122 ‘seed’ sequence-targeting
region
PNAs anti-miR122 (N-term)50-PNA sequence–30(C-term)
Cys-K-PNA23mer-K3 Cys-K-ACAAACACCATTGTCACACTCCA-KKK
dCys-dK-PNA23mer-dK3 dCys-dK-ACAAACACCATTGTCACACTCCA-dkdkdk
dK-PNA23mer-dK3 dK-ACAAACACCATTGTCACACTCCA-d(KKK)
Cys-K4-PNA23mer Cys-KKKK-ACAAACACCATTGTCACACTCCA
K4-PNA23mer KKKK-ACAAACACCATTGTCACACTCCA
Cys-PNA23mer-K4 Cys-ACAAACACCATTGTCACACTCCA-KKKK
PNA23mer-K4 ACAAACACCATTGTCACACTCCA-KKKK
Cys-K-PNA19mer(50trunc)-K3 Cys-K-ACACCATTGTCACACTCCA-KKK
Cys-K-PNA18mer(50trunc)-K3 Cys-K-CACCATTGTCACACTCCA-KKK
Cys-K-PNA17mer(50trunc)-K3 Cys-K-ACCATTGTCACACTCCA-KKK
Cys-K-PNA23mer(6MM at 50)-K3 Cys-K-TGTTTGACCATTGTCACACTCCA-KKK
Cys-K-PNA17mer(30trunc)-K3 Cys-K-ACAAACACCATTGTCAC-KKK
Mature miR-122 sequence (30-50) UGUUUGUGGUAACAGUGUGAGGU
‘seed’
Note that while PNA sequences are written from 50/N-term to 30/C-term, the mature miR-122 sequence is indicated from
30 to 50 to show base pairing between the miRNA and the anti-miRs.
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scale on Merck NovaSyn TGR resin preloaded with the
C-terminal Lys (80mmol/g) by using an Intavis ResPep
parallel synthesizer and 1ml polyethylene syringe reactors.
For Fmoc deprotection the resin was treated with a
solution of piperidine/DMF (1:4, 200ml) for 2min fol-
lowed by draining of the reactor. The procedure was
repeated and the resin washed with DMF (3 200ml).
For couplings, stock solutions were prepared: PNA
monomers in NMP (0.2M), Fmoc-Lys(Boc) in NMP
(0.3M), Fmoc-TO-monomer in NMP (0.2 M), HCTU in
NMP (0.3M), NMM in DMF (4M). Solutions were
combined for preactivation (6 eq Lys, 5.4 eq HCTU, 18
eq NMM or 4 eq PNA monomer, 3.6 eq HCTU, 12 eq
NMM) and after 2min transferred to the syringe reactor.
The reactor was drained after 30min. Double coupling
and triple coupling was used when necessary. The resin
was washed with DMF (3 200ml). For capping, the
resin was treated with DMF/acetic anhydride/
2,6-lutidine (89:5:6, 200ml) for 2min, and washed with
DMF (3 200ml). For ﬁnal cleavage the resin was washed
with CH2Cl2 (10 200ml), and dried. The resin was treated
for 1h with a solution of L-cysteine methyl ester hydro-
chloride (7.5mg) in TFA/m-cresol/water (93:5:2, 200ml).
After draining, the resin was washed with TFA
(2 200ml). Work-up and puriﬁcation was performed as
previously described (35). Cys-K-(TO)PNA-K3 and
K-(TO)PNA-K3 were synthesized at 40mmol scale as pre-
viously described (22) but with manual coupling of the
TO-PNA monomer. BoPhpC-PNA was synthesized puri-
ﬁed and characterized as previously described (36). Brieﬂy,
PNAs were synthesized using an Applied Biosystems 433A
peptide synthesizer and standard Fmoc chemistry on a
10mmol scale and on a Rink amide resin. Crude oligomers
were puriﬁed by RP-HPLC and their identities conﬁrmed
by HRMS (ESI-TOF). For PNA Cys-alkylation, 100
nmoles PNA ONs dissolved in water was incubated for
10min at room temperature with 10 equivalents
N-ethylmaleimide (NEM). The reaction was monitored by
MALDI-TOF mass spectrometry. Upon completion, the
reaction was puriﬁed by RP-HPLC, the product
lyophilized and re-suspended in water.
Cell culture and transfections
Huh7 cells and HEK293ET cells were maintained in
Dulbecco’s modiﬁed eagle medium containing 10%
foetal bovine serum and Penicillin/Streptomycin antibiot-
ics (Full Media: DMEM/FBS/PenStrep) at 37 C/5% CO2.
Lipofections were carried out for 4h using Lipofectamine
2000 following the manufacturer’s protocols in 150ml ﬁnal
volume of transfection. Following lipofection, cells were
washed with PBS and media was replaced by Full Media.
All PNA ONs were delivered in the absence of transfec-
tion agents in serum-free media (opti-MEM) unless stated
otherwise, as described previously (32).
Luciferase assays
MiR-122 dual luciferase reporter system and luciferase
assays was described previously (32). Unless stated other-
wise, Huh7 cells were lipofected with 100ng miR-122 dual
luciferase plasmid and the next day washed and incubated
with PNA anti-miRs for 4h in serum-free media (opti-
MEM). After PNA incubation, cells were washed and
grown in Full Media until luciferase measurements were
carried out. All experiments were carried out in triplicate.
Assays with endocytosis inhibitors
Huh7 cells were plated and lipofected with miR-122
dual-luciferase reporter construct as described previously
(32). Cells were washed once with PBS and were incubated
for 2h with 5mM Cys-K-PNA23mer-K3 in 100ml opti-
MEM or 100ml of either 30mM chlorpromazine (CPZ),
2.5mM methyl-b-cyclodextrin (MBCD), 0.45M sucrose
or 2.5mg/ml Latrunculin B. All the inhibitor solutions were
freshly made up in opti-MEM just before use. For speciﬁc
inhibition of clathrin-mediated endocytosis (CME), Huh7
cells were co-lipofected with miR-122 dual luciferase
reporter construct and with 100ng AP180-C construct
(37) and PNA incubation was carried out the next day
in opti-MEM. For AP180-C plus MBCD treatment,
Huh7 cells were pre-incubated for 1h in opti-MEM or
opti-MEM containing 2.5mM MBCD before addition of
PNA and cell incubation with PNA was carried out for
1h. After PNA incubations, cells were washed twice with
PBS and 200ml Full Media was added. 2h later media was
again replaced by 200ml Full Media. Luciferase expression
was measured 48h after PNA incubation.
Assays with chloroquine and calcium
Huh7 cells expressing miR-122 dual luciferase reporter
construct were incubated for 4h with 1 or 5mM Cys-K-
PNA23mer-K3 in 100ml opti-MEM in the presence or
absence of 6mM CaCl2 or 100mM chloroquine. After
PNA incubation media was replaced by Full Media.
Luciferase expression was carried out 48h after PNA in-
cubation. For Figure 5B, PNA-treated cells were washed
twice with 150ml PBS and media was replaced by 100ml
opti-MEM in the presence or absence of 6mM CaCl2 but
without PNA present. Four hours later, cells were washed
and media was replaced by Full Media and Luciferase
expression measured after 48h.
Cell viability assays
Cell viability assays were carried out using CellTiter 96
AQueous One Solution Cell Proliferation Assay
(Promega; cat number 63582) following the manufactur-
er’s protocol (see Supplementary Methods). The assay is
based on the MTS tetrazolium reagent.
FACS analysis
Huh7 or HEK293ET cells were incubated with 3mM
TO-PNA anti-miRs in opti-MEM for 4h, after which
media was replaced by Full Media (see Supplementary
Methods). After 24h of PNA incubation, FACS analysis
was performed in a FACSCalibur analyzer measuring
10000 gated events per sample. TO-PNA ﬂuorescence
was recorded by excitation at 488nm (argon laser) and
detection at 530nm. Data was processed using FlowJo
version 9.3.2.
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Huh7 cells were plated, plasmid transfected and in-
cubated with TO-PNA or BoPhpC-PNA as described in
Supplementary Methods. Before visualization by confocal
microscopy, cells were washed and ﬁxed with 4% EM-
grade paraformaldehyde (PFA; Electron Microscopy
Sciences). We obtained similar results when performing
live imaging (data not shown). For transferrin co-
localization studies, Alexa 594-conjugated human trans-
ferrin (Invitrogen; T-13343) at 50mg/ml was mixed with
Cys-K(TO) PNA-K3 at 3mM in opti-MEM clear media
(no phenol red). Cells were incubated with 200ml
transferrin/TO-PNA solution for 1.5h and then washed
3 times with 200ml PBS, ﬁxed, nuclei stained and visual-
ized by confocal microscopy. Additional detailed proto-
cols in Supplementary Methods.
Cell fractionation and Immuno-precipitation
Cell fractionation and immunoprecipitation (IP) experi-
ments were based on Steuble et al. (38) with some modi-
ﬁcations (see Supplementary Methods). For Figure 7A,
the membrane fraction was resuspended in 12ml HB,
while for IP (Figure 7B) it was suspended in 3.5ml HB.
For STX13 plus antigen IP experiment (Figure 7B, lane 5),
beads were incubated with 5mg pure STX13 protein
(Synaptic Systems; 110-13P) in 500ml ﬁnal volume HB
for 30min at 4 C prior to incubation with membrane
fraction sample.
RNA extraction and protein extraction
RNA was extracted using TRIzol LS (Invitrogen) follow-
ing the manufacturer’s protocols. The obtained RNA
pellet was re-suspended in water and was re-precipitated
as described previously (39). Quantiﬁcation was carried
out using a NanoDrop 2000 spectrophotometer (Thermo
Scientiﬁc). For protein extraction, 200ml sample obtained
after cellular fractionation or IP were thoroughly mixed
with 600ml methanol (MeOH) and 100ml chloroform.
Then 600ml water was added and mixed. Samples were
centrifuged for 5min at room temperature at 13000rpm
for phase separation. The upper phase was discarded.
600ml MeOH was added to the remaining phases, mixed
and centrifuged for 15min at room temperature at
13000rpm. The supernatant was discarded and the pellet
was air-dried. Samples obtained after IP experiments were
re-suspended in 35ml4   NuPAGE LDS sample buffer
(Invitrogen) and were not quantiﬁed. Samples obtained
after cell fractionation were re-suspended in 1% SDS
and quantiﬁed using a QuantiPRO BCA assay kit
(Sigma) following the manufacturer’s protocol.
Western blot and antibodies
Western blots were carried out using standard procedures
(see Supplementary Methods). Primary antibodies used:
anti-Rab5 (Sc-46692; Santa Cruz Biotechnology) used at
1:2000 dilution, anti-Lamp1 (H4A3; Developmental
Studies Hybridoma Bank) used at 1:10000, anti-Golgin
(A-21270; Molecular Probes/Invitrogen) used at 1:1000
dilution, anti-p97 (MA1-21412; Pierce/Thermo Scientiﬁc)
used at 1:2000 dilution, anti-STX13 (110132; Synaptic
Systems) used at 1:10000 dilution. For IP experiments,
IgG heavy chain was detected when the membrane was
incubated with anti-STX13 (cross-reaction). All secondary
antibodies were ZyMax IgG (H+L) HRP Conjugated
(Invitrogen) and were used at 1:3000 dilution. All
antibodies were diluted in PBS/0.1% Tween20/5% Milk.
North-western blot
Proteins were extracted and electrophoresed in protein
gels as described above (and Supplementary Methods).
After gel transfer, the lower portion of the membrane
(below 17KDa in size) was cut and incubated in
UltraHyb Oligo hybridization buffer (Ambion/Applied
Biosystems; AM8663) for 30min at 42 C. Then,
250pmol of an RNA oligonucleotide having the same se-
quence as miR-122 (see above) was 50-end-radiolabeled
using [g-
32P]ATP and added to the membrane-containing
hybridization buffer. The membrane was left hybridizing
with the radiolabeled probe overnight at 42 C and the
next day washed as previously described (39) and
exposed to X-ray ﬁlms.
Northern blot
Northern blots were carried out as previously described
(30,39) with one modiﬁcation: 2.5mg of RNA was dis-
solved in 8M urea/20% formamide loading dye and sam-
ples were loaded in 15% TBE-Urea pre-cast gels
(Invitrogen) and ran for 65min at 180V.
miR-122 reverse transcription quantitative real-time PCR
Quantiﬁcation of miR-122 by quantitative real-time PCR
(RT–qPCR) was carried out essentially as described pre-
viously (30) with some modiﬁcations. Absolute miR-122
quantiﬁcation method was carried out using a calibration
curve that was prepared by performing serial dilutions of a
single stranded RNA oligonucleotide having the same
sequence as miR-122. A 5ml sample was used for cDNA
synthesis. Then 9ml cDNA taken immediately from the
cDNA reaction was combined with 11ml qPCR Master
mix for qPCR step.
RESULTS
PNA anti-miR and attached amino acid requirements
for efﬁcient miR-122 inhibition in cells
We described recently a convenient reporter system for
assessing the potency of anti-miRs against miR-122 (32),
which is based on a dual-luciferase miRNA sensor assay
(20). Brieﬂy, a miR-122 recognition site, perfectly comple-
mentary to the full mature miR-122 sequence was inserted
at the 30-untranslated region (UTR) of Renilla Luciferase
(RLuc) to bring RLuc under the control of miR-122 (re-
pressed luciferase expression). In this construct, a second
luciferase gene is present (Fireﬂy; FLuc) that is not under
miR-122 regulation and which serves as an internal
control. When this dual-luciferase construct is introduced
into miR-122 positive cells (e.g. Huh7 cells), RLuc is re-
pressed. Upon addition of an anti-miR, de-repression of
Nucleic Acids Research,2012, Vol.40, No. 5 2155RLuc is observed as a consequence of anti-miR binding
to miR-122, leading to an increase in relative RLuc/FLuc
ratio (32). Such an approach has become widely used to
measure anti-miR activity (20,21,32–34,40).
Dual-luciferase reporter Huh7 cells were incubated with
increasing amounts of Cys-K-PNA23mer-K3 anti-miR for
4h in serum-free media in the absence of a transfection
agent, followed by cell growth in Full Media for 2 days in
the absence of added PNA. This showed dose-dependent
RLuc de-repression (miR-122 inhibition) by the PNA
anti-miR (Figure 1A). MiR-122 inhibition was seen at
sub-micromolar concentrations, as reported recently
(32), with saturation above 1mM anti-miR concentration.
Importantly, Cys-K-PNA23mer-K3 did not show any stat-
istically signiﬁcant decrease in cell viability up to 10mM
(one-way ANOVA with Dunnet’s multiple comparison
test) (Figure 1B).
We then asked whether the presence of the N-terminal
Cys residue, the positioning of the Lys residues or use of
D-amino acids have an effect on anti-miR activity.
Dual-luciferase reporter Huh7 cells were treated as
before with different cationic PNA anti-miRs (Table 1)
at 1mM, a concentration just below anti-miR activity sat-
uration to ensure maximal dynamic range. Whereas use of
all D-amino acids (dCys-dK-PNA23mer-dK3) led to only
a mild reduction in miR-122 inhibition (Figure 2A), add-
itional removal of the terminal Cys (dK-PNA23mer-dK3)
reduced activity dramatically. Positioning of the Lys
residues at the N-terminus of the PNA anti-miR also
showed a detrimental effect (Cys-K4-PNA23mer) as
compared to the PNA anti-miR containing all four
Lys residues at the C-terminus (Cys-PNA23mer-K4).
Similarly, upon removal of the terminal Cys, the activity
in each case was substantially reduced (K4-PNA23mer
and PNA23mer-K4) (Figure 2A). Comparable activity
levels were obtained for experiments with PNA
anti-miRs with all D-amino acids when pre-incubated
with 10% foetal bovine serum (FBS) for 2h and then
added to reporter Huh7 cells for 4h also in 10% FBS
(Figure 2B), suggesting that the cellular uptake of these
PNA anti-miRs is not affected by serum proteins. In the
case of anti-miR lacking the terminal Cys (dK-
PNA23mer-dK3) a higher concentration was used
(5mM) to obtain a better activity comparison between
untreated [(-) control] and dK-PNA23mer-dK3 treated
cells, but no difference was also seen at 1mM (data not
shown).
The activity of Cys-K-PNA-K3 was reduced as the
length of the ON was shortened (Figure 2C). However,
even a 19-mer PNA anti-miR containing a 4-nucleotide
truncation at the 50-end of the anti-miR [Cys-K-
PNA19mer (50trunc)-K3] was still able to inhibit miR-
122 signiﬁcantly. Interestingly, a 6-nucleotide truncation
at the 50-end of the anti-miR [Cys-K-PNA17mer
(50trunc)-K3] was better tolerated than an equivalent 6 nu-
cleotides mismatch in that position [Cys-K-PNA23mer
(6MM at 50)-K3]. Also, a 6-nt truncation at the 50-end of
the anti-miR [Cys-K-PNA17mer (50trunc)-K3] was better
tolerated than a 6-nt truncation at 30-end of the anti-miR
[Cys-K-PNA17-mer (30trunc)-K3]. This highlights the im-
portance of targeting the ‘seed’ sequence of the miRNA
(Table 1). All the PNA anti-miRs showed similar melting
temperatures when hybridized against a fully complemen-
tary RNA strand containing the same sequence as miR-122
(Supplementary Table S1). This suggests that there are
factors involved in efﬁcient targeting of miRNAs beyond
the RNA binding afﬁnity of the anti-miR.
Thiol-dependent enhanced cellular uptake for cationic
PNA anti-miRs
We further investigated the function of the terminal Cys
residue in PNA anti-miRs and asked if the enhanced anti-
miR activity is due to the presence of a free thiol group.
PNA23-mer anti-miR was alkylated at the Cys residue
using N-ethylmaleimide (NEM) and the anti-miR added
to dual luciferase reporter Huh7 cells at 1mM concentra-
tion for 4h as before. Alkylation (dCys(NEM)-dK-
PNA23mer-dK3) led to a dramatic loss in anti-miR
activity (Figure 3A), similar to that of dK-PNA23mer-
dK3 anti-miR lacking a Cys residue (Figure 2A).
Similarly, replacement of the Cys by Met, which contains
a methylated thiol group (Met-K-PNA23mer-K3), or by
Ser (Ser-K-PNA23mer-K3) resulted in each case in a sub-
stantial reduction in anti-miR activity (Figure 3A). In
contrast, activity was completely recovered when the Cys
was replaced by 3-mercaptopropionic acid (MPA-K-
PNA23mer-K3). These data strongly suggest that the
enhanced PNA anti-miR activity for Cys-containing
Figure 1. (A) Dose-dependent up-regulation of luciferase expression in Huh7 cells treated with Cys-K-PNA23mer-K3 in the absence of transfection
agents. (B) Toxicity assay for Huh7 cells treated as in (A).
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thiol group.
We asked whether the activity increase obtained with a
terminal free thiol group was due to enhanced cellular
uptake or improved miRNA targeting following cell in-
ternalization. For these studies, we made use of a ﬂuores-
cent PNA in which a PNA nucleobase is replaced by
thiazole orange (TO) (41–43) (Supplementary Figure 1A).
The TO dye is able to behave as universal base (41).
Moreover, the ﬂuorescence emission of the TO-PNA
monomer in the context of a PNA ON is enhanced upon
binding to a complementary DNA or RNA strand
in vitro (41–43) and in cells (43). We carried out a scan
of K-PNA19mer-K3 anti-miR by replacement of individ-
ual PNA units at different sequence positions by the
TO-PNA monomer and by measurement of the ﬂuores-
cence differences when the PNA is single-stranded
(ss-PNA) or in a duplex with a complementary miR-122
RNA (PNA–RNA duplex) at 25 or 37 C (Supplementary
Figure S1B and C). A 19-mer anti-miR containing a
TO-PNA monomer at the second to last position at the
50-end [PNA 17, K-(TO)PNA-K3] was amongst the best
TO-PNA anti-miRs in terms of ﬂuorescence enhance-
ment upon RNA binding. The K-(TO)PNA-K3 anti-
miR also showed enhanced ﬂuorescence by confocal
microscopy as compared to the other TO-PNA anti-
miRs (data not shown). Further, the K-(TO)PNA-K3
was one of the most active TO-PNA anti-miRs as seen
by luciferase up-regulation measurements (data not
shown). Importantly, the Cys-K-(TO)PNA-K3 main-
tained much of the anti-miR activity as compared to
Cys-K-PNA19mer-K3 (Figure 3B). Removal of the ter-
minal Cys residue [K-(TO)PNA-K3] or alkylation of the
terminal Cys [Cys(NEM)-K-(TO)PNA-K3] led to a sub-
stantial loss in anti-miR activity, just as for unmodiﬁed
PNA anti-miRs (Figure 3B, compared with Figures 2A
and 3A).
When Huh7 cells were incubated with 3mM Cys-K-
(TO)PNA-K3, with the anti-miR lacking Cys [K-
(TO)PNA-K3] or with the alkylated Cys anti-miR
[Cys(NEM)-K-(TO)PNA-K3] under standard 4h/24h in-
cubation conditions, FACS analysis showed that the
relative median ﬂuorescence was 35.5±5.4 for Huh7
cells treated with Cys-K-(TO)PNA-K3, but only
9.4±1.7 and 4.9±0.5 for cells treated with K-(TO)
PNA-K3 or Cys(NEM)-K-(TO)PNA-K3, respectively
(Figure 3C, left panel and 3D). This suggested enhanced
uptake of the Cys-containing PNA. However, under these
conditions, the median ﬂuorescence is dependent on cellu-
lar uptake of the anti-miR and dependent on binding of
the TO-anti-miR to miR-122. We therefore carried out the
same experiment on HEK293ET cells that do not express
the RNA target miR-122. We found that the relative me-
dian ﬂuorescence was also much higher for HEK293ET
cells after treatment with Cys-K-(TO)PNA-K3 (28.3±
0.1) as compared to K-(TO)PNA-K3 (2.9±0.2) or
Cys(NEM)-K-(TO)PNA-K3 (2.1±0.2) (Figure 3C, right
panel and 3D). Similarly, the relative median ﬂuores-
cence was higher for Cys-K-(TO)PNA-K3 than for
K-(TO)PNA-K3 in undifferentiated (myoblast) or dif-
ferentiated (myotubes) H2K mdx mice-derived muscle cells
(data not shown). We also carried out confocal micros-
copy on Huh7 cells treated with the TO-PNA anti-miRs to
verify that the observed ﬂuorescence by FACS was
detected inside the cells and not bound externally to the
Figure 2. (A) Effect of Cys, D-amino acids and positioning of Lys
residues on Cys-K-PNA23mer-K3 anti-miR activity as seen by luci-
ferase assay. Huh7 cells were treated with 1mM PNAs. (B) Luciferase
assay of Huh7 cells treated with dPNAs at the indicated concentrations
in the presence or absence of 10% FBS. (C) Effect of truncations and
mismatches on Cys-K-PNA-K3 anti-miR activity as seen by luciferase
assay. Huh7 cells were treated with 1mM PNAs.
Nucleic Acids Research,2012, Vol.40, No. 5 2157Figure 3. (A) Effect of Cys modiﬁcation or replacement within Cys-K-PNA23mer-K3 on anti-miR activity as seen by luciferase assay. Huh7 cells
were treated with 1mM PNAs. (B) Luciferase activity assay for 1mM TO-PNAs as compared to a sequence-equivalent unmodiﬁed PNA anti-miR.
(C) Representative FACS histogram for Huh7 (left panel) or HEK293ET (right panel) cells treated with TO-PNAs at 3mM. (D) Median ﬂuorescence
relative to untreated cells observed for Huh7 cells and HEK293ET cells treated as in (C) by FACS analysis; shown are results of three independent
experiments. (E) Confocal microscopy of Huh7 cells treated with TO-PNAs at 3mM. Green, TO-PNAs; blue, Hoechst staining; red, Cell Mask
plasma membrane staining. Scale bar corresponds to 5mm. All three images were taken with the same confocal microscopy settings.
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inside the cell in vesicular shapes in the cytosol but ﬂuor-
escence was not observed in the nucleus or plasma mem-
brane. In agreement with FACS, cells treated with Cys-K-
(TO)PNA-K3 were more ﬂuorescent than cells treated
with K-(TO)PNA-K3 or Cys(NEM)-K-(TO)PNA-K3.
Confocal microscopy on HEK293ET cells also showed
Cys-K-(TO)PNA-K3 anti-miR ﬂuorescence only inside
cells (data not shown). Overall, the data are strongly con-
sistent with the view that the terminal Cys residue enhances
PNA anti-miR cell uptake. Moreover, this seems to be a
general feature for several cell lines.
Endocytosis of Cys-K-PNA23mer-K3
Dual-luciferase reporter Huh7 cells were incubated with
0.5mM Cys-K-PNA23mer-K3 (a concentration at which
PNA activity is sub-saturating, Figure 1A) for various
times up to 240min in serum-free media. After PNA in-
cubations, cells were washed thoroughly to remove un-
delivered PNA, media replaced by Full Media and
Luciferase expression measured after 48h as before. The
activity data plotted against time ﬁt to a sigmoidal-shaped
curve (Figure 4A). A low level of activity (RLuc/FLuc
1.5–2.0) is obtained within 5min of PNA anti-miR incu-
bation, which is followed by a rapid increase after about
15min and reached a plateau by 100min incubation time.
We ruled out the possibility that the low-level activity at
early time-points is due to Cys-K-PNA23-mer-K3 remain-
ing bound to the plasma membrane after washing and
internalized during subsequent cell growth, because in a
control experiment where cells were incubated with Cys-
K-PNA23-mer-K3 for 15min, washed thoroughly and
further incubated for 1h with excess of scrambled Cys-
K-PNA23-mer-K3 control anti-miR as competitor, no
decrease in Cys-K-PNA23-mer-K3 activity was observed
(Supplementary Figure S2).
We then asked whether an endocytotic mechanism was
involved in Cys-K-PNA23-mer-K3 uptake. To do this,
dual-luciferase reporter Huh7 cells were incubated for
2h with 5mM Cys-K-PNA23-mer-K3 (saturating condi-
tions of activity) in media containing one of a number
of endocytosis inhibitors (Figure 4B). Use of hypertonic
media (0.45M sucrose) completely abolished the PNA
anti-miR activity. However incubation in the presence
of 30mM chlorpromazine (CPZ), 5mg/ml Latrunculin B
(LatB) or 2.5mM methyl-b-cyclodextrin (MBCD) only
partially reduced Cys-K-PNA23mer-K3 anti-miR
activity ( 40% reduction). Similar results were obtained
in each case when the cells were pre-incubated with inhibi-
tor for 1h followed by incubation with PNA anti-miR for
1h in the presence of inhibitor (data not shown). A total
of 0.45 M sucrose is a general inhibitor of endocytosis and
mainly blocks CME, but it has also been shown to block
ﬂuid-phase endocytosis in ﬁbroblasts (44) and to inhibit a
clathrin-independent mechanism of receptor-mediated
endocytosis in ependymoma cells, possibly by disturbing
actin ﬁlaments (45). High sucrose was shown to reduce
uptake of another cationic PNA (K8-PNA-K3) in HeLa
cells (46). CPZ is thought to inhibit CME as it blocks
uptake of transferrin (a typical marker for CME) (47).
LatB prevents actin polymerization involved in CME
but mainly in clathrin-independent endocytotic mechan-
isms (48). Finally, MBCD removes cholesterol from the
cell plasma membrane also affecting mainly clathrin-
independent endocytosis (CIE) (48). A similar reduction in
Cys-K-PNA23mer-K3 activity in the presence of MBCD
was seen when the cells were incubated with the PNA
anti-miR for 15min (early PNA anti-miR uptake time
point) (Supplementary Figure S3A) suggesting that there
is no difference in cell entry mechanism for Cys-K-
PNA23mer-K3 at either early or later time points.
To further inhibit CME speciﬁcally, we used a plasmid
construct expressing the C-terminus of the clathrin-
assembly protein AP180 (AP180-C; (37)) that has been
validated as a dominant negative approach for inhibition
of CME (37,49). Huh7 cells containing co-transfected
miR-122 dual luciferase reporter and AP180-C plasmids
and incubated with Cys-K-PNA23mer-K3 anti-miR as
before showed slightly improved activity (Figure 4B).
This suggests that an alternative clathrin-independent
endocytotic uptake mechanism is able to compensate for
Figure 4. (A) Kinetics of uptake for Cys-K-PNA23mer-K3 anti-miR.
Huh7 cells were treated with 0.5mM PNA for the indicated time. Cells
were then washed and luciferase expression was measured 48h after
PNA incubation. (B) Effect of endocytosis inhibitors on Cys-K-
PNA23mer-K3 uptake as seen by luciferase assay. CPZ: chlorpromaz-
ine; Lat B: Latrunculin B; MBCD: Methyl-b-cyclodextrin; AP180-C:
dominant-negative form of AP180.
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uptake (50,51). When over-expression of AP180-C
during cell incubation with Cys-K-PNA23mer-K3 was
combined with MBCD treatment, to inhibit general
CIE, activity was completely abolished, which suggests
complete loss of productive cellular uptake (Figure 4B).
Such cell incubation conditions did not affect cell viability
(Supplementary Figure 3B). Overall the inhibitor data
suggest that Cys-K-PNA23-mer-K3 is internalized in
Huh7 cells by CME but can also enter productively to
reach miR-122 by a clathrin-independent but actin- and
cholesterol-dependent mechanism of endocytosis.
Endosome trapping does not signiﬁcantly affect
Cys-K-PNA23mer-K3 anti-miR activity
We asked whether following PNA internalization, endo-
some trapping would limit the efﬁciency of Cys-K-PNA-
K3 anti-miR. Dual-luciferase reporter Huh7 cells were
incubated with 1 or 5mM Cys-K-PNA23-mer-K3 for 4h
in the presence or absence of 100mM chloroquine or 6mM
CaCl2, conditions reported to increase endosomal release
and nuclear splicing inhibitory activity of cationic PNA
(46,52) (Figure 5A). Chloroquine had only a small effect
on Cys-K-PNA23mer-K3 anti-miR activity, whereas cal-
cium ion addition led to a very signiﬁcant increase in
Cys-K-PNA23mer-K3 anti-miR activity. Since an increase
in cytosolic calcium ion concentration has been shown to
stimulate CME and CIE in pancreatic b-cells (53) and to
accelerate endocytosis of vSNARES (54), we asked if the
calcium ion–induced increase in Cys-K-PNA23-mer-K3
anti-miR activity is due to enhanced cellular uptake of
the PNA. Thus, dual-luciferase reporter Huh7 cells were
incubated for (i) 4h with 5mM Cys-K-PNA23-mer-K3
followed by a further 4h in the absence of PNA, or
(ii) 4h with PNA and 6mM calcium ions followed by a
further 4h incubation in 6mM calcium ions in the
absence of PNA, or (iii) 4h with PNA alone followed
by incubation with 6mM calcium for 4h in the
absence of PNA (Figure 5B). Careful cell washings were
carried out between incubations to prevent carry-over.
The contribution to Cys-K-PNA23-mer-K3 anti-miR
activity in the presence of calcium ions due to endosomal
release (condition iii) was small and similar to the effect of
chloroquine (Figure 5A; 5mM PNA), whereas the activity
stimulation was much larger under condition ii, when
calcium ions were present at the start. These results
suggest that endosomal trapping does not signiﬁcantly
affect Cys-K-PNA23-mer-K3 anti-miR activity and that
the predominant effect of calcium ions in Huh7 cells is to
stimulate PNA endocytosis. Note that we were able to
verify that for Cys-K-(TO)PNA-K3 chloroquine treatment
of Huh7 cells results in a pattern of ﬂuorescence consistent
with partial endosomal release, but we were unable to
carry out the same veriﬁcation for calcium ions as we
found the TO ﬂuorescence to be quenched inside Huh7
cells in the presence of calcium ions (data not shown).
Subcellular localization of PNA anti-miRs
MiRNAs were found associated with endosomal compart-
ments as well as cytoplasmic foci known as P-bodies and
GW-bodies (13,14,55). We therefore asked whether target-
ing of miRNA by PNA anti-miR might occur within these
compartments. To test if Cys-K-(TO)PNA-K3 is found in
early endosomes, Huh7 cells were co-incubated with Cys-
K-(TO)PNA-K3 and ﬂuorescently labelled transferrin for
1.5h. Cells were thoroughly washed, ﬁxed, nuclei were
stained and cells were visualized by confocal microscopy.
Cys-K-(TO)PNA-K3 was found to co-localize with trans-
ferrin in small vesicles likely to be early endosomes and
thus consistent with CME (Figure 6A). In a second experi-
ment, Huh7 cells were incubated with Cys-K-(TO)PNA-
K3 for 4h. Twenty-four hours later, lysosomes and
nuclei were stained, and cells were ﬁxed and visualized
by confocal microscopy (Figure 6B). The results showed
that the PNA was co-localized with lysosomes, implying it
had travelled through the complete endocytotic pathway.
Since P-bodies and GW-bodies were suggested to asso-
ciate with endosomal compartments (55), we investigated
whether PNAs colocalize with these cytoplasmic struc-
tures. Due to ﬂuorescence compatibility issues between
Figure 5. (A) Effect of 100mM chloroquine or 6mM CaCl2 on Cys-K-PNA23mer-K3 anti-miR activity as seen by luciferase assay. Huh7 cells were
incubated with the indicated amounts of PNA in the presence or absence of chloroquine or CaCl2.( B) Effect of CaCl2 on Cys-K-PNA23mer-K3
anti-miR activity due to increase of endocytotic uptake or enhanced endosomal escape (see text for details) as seen by luciferase assay.
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utilized an alternative ﬂuorescent PNA unit, [bis-o-
(aminoethoxy)phenyl]pyrrolocytosine (BoPhpC) (36)
(Supplementary Figure S4A) that has been used for
PNA localization in cells (56). BoPhpC-PNA anti-miR
exhibited similar activity as K-(TO)PNA-K3 in the
miR-122 dual luciferase reporter system (Supplementary
Figure S4B). BoPhpC-PNA was able to enter Huh7 cells
in the absence of transfection agents and co-localized with
K-(TO)PNA-K3 (Supplementary Figure S4C). Confocal
microscopy showed that BoPhpC-PNA was also found
in early and late endosomes as seen by co-localization
with ﬂuorescently labelled transferrin and LysoTracker,
respectively (Supplementary Figure S4D and E). Huh7
cells expressing pcNEGFP-hDcp1a (a plasmid expressing
the human decapping enzyme 1 as a P-body marker (57))
or GFP-GW182 (58) were incubated with BoPhpC-PNA
for 1 - 4h and confocal microscopy was carried out at 2, 4,
6, 8, 10 and 24h after PNA incubation. No co-localization
with P-bodies or GW-Bodies was detected under these
conditions (Figure 6C and D).
We were unable to test whether PNA anti-miR
co-localizes with miR-122 by in situ hybridization for
miRNA detection, since the miRNA is not detected by
Figure 6. (A) Confocal microscopy of Huh7 cells co-incubated with 3mM Cys-K-(TO)PNA-K3 and 50mg/mL Alexa 594-conjugated human trans-
ferrin for 1.5h. (B) Confocal microscopy of Huh7 cells treated with 3mM Cys-K-(TO)PNA-K3 observed at 24h after PNA treatment; lysosomes were
stained using LysoTracker Red. (C) Representative image of confocal microscopy of Huh7 cells expressing P-body marker (pcNEGFP-hDcp1a)
treated with 3mM BoPhpC-PNA. (D) Representative image of confocal microscopy of Huh7 cells expressing GW-body marker (GFP-GW182)
treated with 3mM BoPhpC-PNA.
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(33). Instead, we carried out cellular fractionation on
Huh7 cells treated with Cys-K-(TO)PNA-K3 48h after
PNA incubation. Nuclei and cell debris were ﬁrst
separated from cytoplasm by centrifugation, which was
then divided into membrane-bound compartments
(‘pellet’) and the remaining cytosol (‘supernatant’) by
ultracentrifugation. Proteins and RNA were extracted
from each fraction and analyzed by western blot and
northern blot, respectively. PNA ONs may be recovered
by standard protein extraction and detected by electro-
phoresis as discrete bands in standard protein gels after
western blotting by use of a radiolabeled RNA comple-
mentary probe (north-western blot), similarly to a
previous report (59). In western blotting, there was enrich-
ment in the ‘pellet’ fraction of markers for
membrane-bound compartments including Rab5 (early
endosomes), Syntaxin13 (STX13; recycling endosomes),
Lysosomal-associated membrane protein 1 (LAMP1; late
endosomes/lysosomes) and Golgin (Golgi apparatus)
(Figure 7A). As a control, we detected p97, a cytosolic
AAA-ATPase that associates with endoplasmic reticulum
(ER) for ER-associated protein degradation (ERAD) (60),
which is expected to be present in both the ‘pellet’ and
‘supernatant’ fractions. Cys-K-(TO)PNA-K3 was also
detected in the ‘pellet’ fraction as seen by the
north-western blotting approach. Note that Cys-K-
(TO)PNA-K3 was detected as two bands instead of one,
similarly to the reported detection of a PNA ON
conjugated to a cationic cell penetrating peptide,
whereas a charge neutral PNA ON of the same sequence
was detected as a single band (59). Finally, northern
blotting showed enrichment of mature miR-122 in the
‘pellet’ fraction as compared to the ‘supernatant’, in agree-
ment with mature miRNAs being found within endosomal
compartments (55). The same results were obtained
for cellular fractionation of Huh7 cells treated with
K-(TO)PNA-K3 (without Cys) (data not shown).
We have been unable to date to fully separate different
endosomal compartments using continuous or discontinu-
ous opti-prep gradients (data not shown). Instead we
carried out IP to discriminate between endosomal and
other membrane-bound compartments, such as Golgi or
endoplasmic reticulum. Protein A coated beads were
incubated with a STX13 anti-serum and then the
anti-STX13-containing beads were incubated with the
‘pellet’ fraction to recover endosomal vesicles (mainly
recycling but also early and late endosomes). Elution of
the STX13-positive compartments was carried out either
by treatment with a mild detergent (Triton X-100) to elute
the internal components of the vesicles and part of
trans-membrane proteins, or by a pH shock to break the
bead-antibody bond to recover IgG and STX13-positive
components. Endosomal markers Rab5 and Lamp1 were
detected when the samples were eluted with either Triton
X-100 treatment or pH shock (Figure 7B). Pre-treatment
of anti-STX13-containing beads with STX13 antigen mostly
abolished the detection of these markers. As expected, IgG
was detected only under pH shock conditions. STX13
could not be detected, since it cross-reacted with the IgG
present in the samples. Both Cys-K-PNA(TO)-K3 and
miR-122 were present in STX13-positive compartments
as seen by north-western blotting and by RT–qPCR, re-
spectively (Figure 7B). Northern blot for miR-122 detec-
tion could not be carried out due to the small amounts of
Figure 7. (A) Representative cell fractionation experiment: protein ana-
lysisbywesternblotshowingenrichmentofmarkersformembrane-bound
compartments in the ‘pellet’ fraction as compared to the ‘supernatant’
(cytosolic) fraction. Cys-K-(TO)PNA-K3 was detected by north-
western blot approach (same gel as western Blot). RNA analysis for
miR-122 detection by northern blot (same samples as protein gels
shown above). (B)Representative experiment of immuno-precipitation
for Syntaxin 13 (STX13)-positive compartments. Top panel: western
blot and north-western blot for detection of endosomal markers and
Cys-K-(TO)PNA-K3, respectively. Input:  20% IP. Bottom panel:
RT–qPCR for miR-122 detection in RNA extracted from samples
treated as in B top panel. Input:  65% IP. Ag: STX13 antigen.
TX-100: TritonX-100 elution (mild detergent). pH: pH shock elution.
2162 Nucleic Acids Research, 2012,Vol.40, No. 5RNA obtained after the IP. Overall these results are fully
consistent with the view that PNA anti-miRs passage
through the endocytotic pathway and target miR-122 in
STX13-positive endosomal compartments.
DISCUSSION
Lys-functionalized PNA anti-miRs are versatile tools to
inhibit miRNAs inside cells without the need for added
transfection agent (22,30,32,39). However, information
has been lacking to date on the PNA and amino acid
sequence requirements for anti-miR activity. Our studies
on PNA anti-miR truncations (Figure 2C), agrees with a
previous study where truncations of a full-length 22-mer
MOE PS anti-miR at the 50-end were better tolerated than
truncations at the 30-end (28). Nevertheless, a large drop in
activity still occurred upon 50-truncation by 3 nucleotides
of MOE PS anti-miRs (28), whereas inhibition of miR-122
remained strong for the 50-truncation of 4 nucleotides
from the PNA anti-miR (19-mer Figure 2C) and was
reduced drastically only for a 6-nt truncation (17-mer).
In contrast, LNA-containing anti-miRs do not need to
target the full-length miRNA to maintain strong anti-
miR activity (21,23,33) and ‘tiny’ all-LNA 8mers targeting
only the seed sequence of miR-21 or miR-122 have been
shown to be very effective in cells and in mice (40). Thus, it
is clear that the difference in length requirements for
anti-miR potency is chemistry dependent. Based on the
available literature and the data presented here, it is rea-
sonable to suppose that the stronger the RNA-binding
chemistry, the greater the ability to tolerate anti-miR trun-
cation whilst still maintaining anti-miR potency.
However, all PNA anti-miRs tested here showed high
melting temperatures with complementary RNA in vitro
(Supplementary Table S1), whilst their anti-miR potencies
were different (Figure 2C). Thus other miRNA targeting
factors beyond the afﬁnity of the anti-miR must play a
strong role in potency determination, as has been sug-
gested previously (28,29,32).
Our data suggest that targeting the ‘seed’ sequence
of the miRNA is crucial for PNA anti-miR activity
(Figure 2C), in agreement with other reports (28,40).
MiRNA loading into miRISC pre-organises the seed
sequence for target recognition (11,12). Further, the
50-end of an siRNA-like duplex or a 50-phosphorylated
21-base DNA guide strand loaded into Ago serves as the
nucleation site for mRNA recognition and binding
(61–63). It seems likely that an anti-miR ﬁrst interacts
with the miRNA seed sequence followed by a ‘zipping-up’
mechanism towards the 30-end of the miRNA to form a
stable miRNA:anti-miR duplex. This would imply that
the targeting by anti-miRs occurs once the miRNA has
been loaded in miRISC (24,25,28,40). Since a 6-nt trunca-
tion at the 50-end of the PNA anti-miR was better
tolerated than an equivalent 6-nt mismatch (Figure 2C),
even though both these PNAs showed almost the same
melting temperature (Supplementary Table S1), it is
likely that the mismatches destabilize the duplex in the
context of miRISC.
Positioning the 4 Lys residues at the N-terminus of
the PNA (Cys-K4-PNA23mer) resulted in a substan-
tial drop in anti-miR activity compared to location
at the C-terminus of the PNA (Cys-PNA23mer-K4)
(Figure 2A). However, substitution of all L-amino acids
by D-amino acids (dCys-dK-PNA23mer-dK3) did not sig-
niﬁcantly affect the anti-miR activity. This is consistent
with our recent demonstration that a PNA anti-miR con-
taining 4 D-Lys could inhibit miR-155 in cells and
in vivo and partially recapitulated the gene expression
proﬁle of miR-155 knockout mice at doses that did not
cause toxicity (22). However, the most striking observa-
tion was that the presence of a terminal Cys (in either L or
D conﬁguration) dramatically enhanced PNA anti-miR
cellular activity (Figure 2A). Interestingly, this was not
due to the particular structure of Cys but due to the pres-
ence of a free thiol group (Figure 3A), leading to enhanced
cellular uptake of the PNA anti-miRs (Figure 3C–E) in
Huh7 liver cells, HEK293ET cells (Figure 3C and D) and
H2K mdx mice-derived muscle cells (data not shown). We
therefore believe that the most likely explanation for the
enhanced anti-miR activity observed for thiol-containing
PNAs is due to improved bulk PNA uptake.
Aubry et al. (64) showed for Cys disulﬁde-conjugated
cell penetrating peptides (CPPs) that thiol/disulﬁde
exchange reactions may occur at the cell surface to
enhance cell entry and they reported higher cell associ-
ation for peptides containing Cys residues, either oxidized
or reduced, as compared to their Cys-free versions, leading
to enhanced internalization. They were also able to intern-
alize a Protein Kinase C peptide inhibitor into CHO K1
cells by addition of an activated Cys residue. We found
also that a disulﬁde-conjugated Cys-K-PNA23-mer-K3
dimer was able to inhibit miR-122 in Huh7 cells as well
as the monomeric version (data not shown), which is con-
sistent with a redox involvement at the plasma membrane.
We have not investigated speciﬁcally whether the enhanced
cellular uptake for Cys-K-PNA-K3 is due to enhanced cell
association. However, when we used confocal microscopy
at different time-points we could only observe TO-PNAs
inside the cell and not associated with the plasma mem-
brane (Figure 3E and data not shown). Nevertheless, since
Cys-K-PNA-K3 is both cationic and thiol-containing, and
since cationic CPPs are known to associate with cells
through negatively charged heparan sulfate-containing
glycosylaminoglycans (65), improved cell attachment
cannot be ruled out as an explanation for the enhanced
cellular uptake observed.
The presence of a thiol group in peptides has been
shown to correlate with enhanced cellular uptake. The
MPG series of peptides have been used to complex
DNA and siRNA and these contain a C-terminal
cysteamide residue that is a pre-requisite for efﬁcient deliv-
ery into cells (66,67). Similarly, internalization of the CPP
Pep-1, used for delivery of protein cargoes, was inhibited
in the absence of its C-terminal cysteamide (68). The
precise role of the cysteamide in MPG and Pep-1 has
not been clearly demonstrated, although it is thought that
it plays a role in stabilising the nanoparticle complex or in
membrane anchoring (66–68). However, our results would
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in cellular delivery for these nanostructures.
Sulfur replacement of non-bridging oxygen atoms in
ONs have also led to enhanced activity and cell delivery
in the absence of transfection agents. For example, lipid-
conjugated thio-phosphoramidates exhibited higher anti-
telomerase activity as compared to lipid-conjugated
phosphoramidate ONs in cancer cells, thought to be due
to enhanced delivery (69). Similarly, DNA PS ONs were
better taken up by mouse B-cells than their PO versions,
which correlated with better cell-surface binding of the PS
ON (70). We showed recently better anti-miR activity for
an LNA/OMe PS anti-miR than an LNA/OMe PO
anti-miR delivered in the absence of transfection agents,
suggesting better cellular uptake (32). Our results here
showing a steep increase in Cys-K-PNA23-mer-K3
anti-miR activity at lower concentrations that reaches a
plateau beyond 1mM PNA (Figure 1A) are similar to the
uptake curves reported by Zhao et al. (70), who argued
that DNA PS ONs may congregate at high-afﬁnity binding
sites on cells. No convincing evidence has yet emerged for
speciﬁc receptor proteins for binding of ONs or PNA, but
our results suggest that proteins capable of interacting
either with free thiols or with phosphorothioates may
help to enhance cell uptake, and this subject deserves to
be explored further.
The extent to which these thiol/sulfur-mediated
enhanced uptake mechanisms are relevant in vivo still
remains to be addressed. We have carried out a prelimin-
ary study on targeting miR-122 in mice by dCys-dK-
PNA23mer-dK3 and dK-PNA23mer-dK3. After a short-
term i.p. dosage protocol of 3 doses on alternating days at
40mg/kg PNA, both PNAs gave rise to a 20% reduction
in cholesterol levels in plasma 10 days after the last injec-
tion as compared to PBS-treated mice (data not shown),
showing that PNA anti-miRs are active in mouse liver.
The reason for the lack of phenotypic activity difference
between these two PNAs is not yet clear. One possibility is
that, in vivo, the presence of a reactive thiol group on the
PNA compromises the enhancement of cell uptake seen in
cell culture, through sequestration by a thiol-reactive pro-
tein perhaps. We are currently investigating long-term
dosage protocols as well as the possibility of delivery of
dCys-dK-PNA23mer-dK3 as disulﬁde-conjugated dimers.
In our cell studies, FACS analysis and confocal micros-
copy (Figures 3 and 6) were greatly aided by use of two
novel ﬂuorescent PNA residues. Intrinsic PNA ﬂuores-
cence has advantages over an attached ﬂuorescent tag to
avoid substantial compromise of activity or alteration of
delivery properties or cell localization (71–74), as well as
eliminating the danger of tag removal during cell delivery
(75). Here, both TO-PNA and BoPhpC-PNA allowed
monitoring of PNA cell delivery and trafﬁcking without
substantial compromise of PNA activity (Figure 3 and 6
and Supplementary Figure S4). A BoPhpC-PNA was
shown previously to inhibit mutant huntingtin protein in
GM04281 cells (56). Our studies are the ﬁrst to use this
ﬂuorescent analogue in efﬁcient inhibition of miRNA
(Supplementary Figure S4). TO-PNAs have recently been
shown to be useful tools for imaging of inﬂuenza H1N1
mRNA in living cells (43). In our work, we report the ﬁrst
intracellular functional activity for TO-PNAs, in this case
for miR-122 targeting (Figure 3B). TO-PNA has an add-
itional advantage in that binding to a complementary
RNA strand restricts depletion of the TO excited state
by hampering twisting motions, resulting in enhanced
emitted ﬂuorescence (43). We conﬁrmed this property
for in vitro RNA binding (Supplementary Figure S1). In
cells, an increased ﬂuorescence emission was detected for
Huh7 cells that express the target miR-122 as compared to
HEK293ET cells that do not express the target miR-122
(Figure 3C and D). To rule out better TO-PNA uptake in
Huh7 cells over HEK293ET cells, we thought to treat
Huh7 cells with a scrambled TO-PNA anti-miR.
However, the precise positioning of the TO-PNA
monomer within the anti-miR sequence affects the ﬂuor-
escence emission properties signiﬁcantly (Supplementary
Figure S1), so such an approach cannot be used.
Although we cannot rule out completely cell-speciﬁc
uptake differences, since TO-PNA anti-miRs were shown
to inhibit miR-122 in Huh7 cells (Figure 3B), it seems
likely that the enhanced median ﬂuorescence detected for
TO-PNAs in Huh7 cells is due to TO-PNAs binding to the
miR-122 RNA target.
The mechanism of cellular uptake for Cys-containing
cationic PNA ONs was investigated. Cys-K-(TO)PNA-
K3 was found to be co-localized with transferrin, which
indicates that the bulk PNA prefers a CME route of entry
(Figure 6A). However, the use of a functional assay is
paramount to determine the pathways of the active
fraction of PNA that can reach the desired RNA target.
Anti-miR activity results showed clear evidence for both
clathrin-dependent and independent uptake pathways for
the active fraction of the PNA, since activity was not fully
blocked by CPZ, LatB or MBCD and completely blocked
only when both CME and CIE were simultaneously in-
hibited (Figure 4B). Interestingly, upon speciﬁc inhibition
of CME through the use of the dominant-negative form of
AP180 (AP180-C) (37), activity of Cys-K-PNA23mer-K3
was enhanced a little, suggesting that the CIE pathway
may lead to slightly more productive PNA delivery.
However, in general both types of pathway led to anti-
miR inhibitory activity. In the absence of endocytosis
inhibitors, the kinetics for productive uptake of Cys-K-
PNA23mer-K3 showed a fast but mild uptake at early
time points (within 5min) that rapidly increased and re-
ached a plateau by 100min incubation times (Figure 4A).
One possibility is that the rapid increase in uptake is due
to endosomal recycling and the plateau stage corresponds
to saturation of the endocytotic machinery. Consistent
with this model, our data suggest that Cys-K-PNA23mer-
K3 internalization at early or late time points occurs
via the same endocytotic mechanism (Supplementary
Figure S3A).
Our data suggest that the mechanisms of cellular target-
ing of miRNA are different from that of mRNA and
pre-mRNA. Koller et al. suggested recently (76) that
RNase-H active MOE/DNA PS gapmers targeted to
mRNA and delivered without transfection agents did
not co-localize with P-bodies and that the bulk of the
ON was found in lysosomes after 24h. However, they
concluded that two endocytotic pathways explained their
2164 Nucleic Acids Research, 2012,Vol.40, No. 5antisense activity data best. The non-productive pathway
led to lysosomes, while the productive uptake involved a
novel pathway that was Adaptor Protein Complex 2
(AP2)-dependent, but clathrin- and caveolae-independent.
For miRNA targeting, activity is clearly achievable
unaided by transfection agents through established endo-
cytotic pathways and there is no evidence for an independ-
ent productive pathway. In the case of pre-mRNA
targeting, we and others have found that the nuclear-
active fraction of cationic PNA for splicing redirection is
internalized predominantly by CME (50,51,77) and
endosome trapping signiﬁcantly limits antisense activity
(46,50,52). For miRNA targeting, the choloroquine ex-
periment showed that promotion of endosomal release into
the cytosol did not signiﬁcantly affect Cys-K-PNA23mer-
K3 anti-miR activity (Figure 5). Although both Cys-K-
(TO)PNA-K3 and BoPhpC-PNA were found in early
and late endosomes (Figure 6A and B and
Supplementary Figure S4), suggestive of endosome trapp-
ing, enough PNA is able to reach and inhibit miR-122
(Figure 3B and Supplementary Figure S4B). Moreover,
we have found that both the PNA anti-miR and also
miR-122 are associated with endosomal compartments
(Figure 7, see below). This provides strong evidence that
targeting of miRNAs by anti-miRs occurs within or
associated with endosomal compartments and does not
require PNA release into the cytosol. Note also that we
showed recently that LNA/OMe PS and other modiﬁed
ONs are also highly active inhibitors of miR-122 in cells at
sub-micromolar concentrations in the absence of transfec-
tion agents (32; Threlfall et al., manuscript submitted for
publication).
How therefore is an anti-miR able to access the miRNA
while travelling through the endosomal pathway?
MiRNAs loaded into miRISC are thought to trafﬁc to
P-bodies following mRNA binding, whereupon Cap and
polyA tails of the repressed mRNA are removed (55). The
complex is then thought to move to GW-bodies, where
miRISC may disassemble. P-bodies and GW-bodies were
shown to often associate with MVBs that may fuse with
the plasma membrane and release miRNAs and mRNAs
into exosomes or, alternatively, trafﬁc to lysosomes for
cargo degradation. BoPhpC-PNA was not seen to co-
localize with P-bodies or GW-bodies (Figure 6C and D),
similarly to a report that antagomiRs did not co-localize
with P-bodies in mouse liver (we note however use of a
marker for GW-bodies, GFP-GW182) (27). Obad et al.
detected tiny-LNA anti-miR-21 delivered without trans-
fection agents as discrete punctate signals in the cytoplasm
of HEK293 cells that, in some cases, co-localized with
FLAG-tagged Ago2 (40). Our cell fractionation studies
showed that both miR-122 and TO-PNAs were enriched
in fractions containing membrane-bound compartments
together with markers for early, recycling and late endo-
somes as well as markers for Golgi and ER (Figure 7A).
Both miR-122 and Cys-K-(TO)PNA-K3 anti-miR were
detected during immunoprecipitation identiﬁcation of
STX13-positive compartments (Figure 7B), indicative
that targeting of miRNAs with anti-miRs may take
place in recycling endosomes. Therefore, anti-miRs are
perhaps able to access the miRNA either by fusion of
anti-miR-containing endosomal vesicles with miRNA-
containing endosomal compartments or by leakage of
enough anti-miR into the compartment where miRNA
passages, possibly at the endosome recycling step.
However, a full understanding of the trafﬁcking and
sub-cellular encounter between PNA anti-miR and its
complementary miRNA will require detailed further in-
vestigation and needs to take account not only of local-
ization of bulk ﬂuorescent anti-miR but also to address
the issue of the active targeting fraction, which is currently
hard to distinguish biophysically.
Our studies have addressed a number of important
aspects of PNA anti-miR design for efﬁcient targeting in
cultured cells and have pointed to the mechanisms of cell
uptake leading to encounter of the target miRNA. To
date, only the outcome for the miRNA upon targeting
by anti-miRs of different chemistries has been addressed
in depth (27,29,39). There is still much to learn on the
mechanisms, localization and structural requirements for
efﬁcient miRNA inhibition in cells and in vivo by anti-
miRs. We hope that our studies on PNA are a useful con-
tribution along this pathway of understanding, and may
help towards design of better therapeutic candidates.
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